Investors

AIM Rule 26 Information

This area of the web site contains all information which is required to be disclosed in accordance with Rule 26 of the AIM Rules.

Shareholder Information

Other Exchanges and Trading Platforms
Shares in Issue
Significant Shareholdings
Director Shareholdings
Shares Not in Public Hands
Restrictions in Transfer of AIM Securities
UK City Code on Takeovers and Mergers

see Shareholder Information

Advisors

see Advisors

Announcements and Notifications

see News

Q&A with LungLife AI's CEO, Paul Pagano

Half-year Report For The Six Months Ended 30 June 2023

Featured News

February 27, 2023

Nodule evaluation using LungLB® projected to be cost-effective in US healthcare system

27 February 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Nodule evaluation using LungLB® projected to be cost-effective in US healthcare system Data strongly support payor coverage of indeterminate lung nodule evaluation using LungLB® in peer-reviewed publication in the Journal of Medical Economics LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung […]

• Read More

February 20, 2023

Preliminary audited results for year ended 31 December 2022

20 February 2023 LungLife AI, Inc. (the “Company” or “LungLife”) Preliminary audited results for year ended 31 December 2022 LungLife to report financial results for full-year 2022 LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces its audited preliminary results for the year ended 31 December 2022. Summary and Highlights […]

• Read More

« Previous 1 … 18 19 20 21 22 … 37 Next »

More News